Drugs for Hemopericardium (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 41)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Diclofenac |
Approved, Vet_approved |
Phase 4 |
|
15307-86-5 |
3033 |
Synonyms:
(2,6-Dichlorophenyl)amino]benzeneacetic acid
[2-(2,6-Dichloroanilino)phenyl]acetate
[2-(2,6-dichloroanilino)phenyl]acetic acid
[2-(2,6-Dichloroanilino)phenyl]acetic acid
[o-(2,6-Dichloroanilino)phenyl]acetic acid
{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid
15307-81-0 (mono-potassium salt)
15307-86-5
2-((2,6-Dichlorophenyl)amino)benzeneacetate
2-((2,6-dichlorophenyl)amino)benzeneacetic acid
2-((2,6-Dichlorophenyl)amino)benzeneacetic acid
2-(2,6-Dichloroanilino)phenylacetic Acid
2-(2,6-Dichlorophenylamino)phenylacetic acid
2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid
2-[2-(2,6-dichloroanilino)phenyl]acetic acid
2-[2-(2,6-Dichlorophenylamino)phenyl]acetic acid
2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID
2b17
AC1L1F0T
Acetic acid, [o-(2,6-dichloroanilino)phenyl]- (8CI)
AKOS001579542
Allvoran
Apo-Diclo
Assaren
Benfofen
Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)- (9CI)
BIDD:GT0380
BPBio1_000516
BRD-K08252256-236-05-6
BRN 2146636
BSPBio_000468
BSPBio_002169
C01690
Cataflam
CHEBI:47381
CHEMBL139
CID3033
cMAP_000014
D07816
D30801
D3748
DB00586
Delphimix
dichlofenac
Dichlofenac
Dichlofenal
Dichronic
Diclac
Diclobenin
diclofenac
Diclofenac
Diclofenac (INN)
Diclofenac [INN:BAN]
Diclofenac acid
Diclofenac Acid
Diclofenac potassium
Diclofenac Potassium
Diclofenac sodium
Diclofenac Sodium
Diclofenac, sodium
Diclofenaco
Diclofenaco [INN-Spanish]
Diclofenacum
Diclofenacum [INN-Latin]
Diclofenamate
Diclofenamic acid
Diclomelan
Diclonate p
Diclonate P
Diclophenac
Diclo-Phlogont
Diclo-Puren
Diclord
Dicloreum
Dicloreuma
Dicrofenac
DIF
DivK1c_000272
DivK1c_000402
Dolobasan
Duravolten
Dyloject
Ecofenac
Effekton
|
EINECS 239-348-5
Feloran
GP-45,840
henyl)-o-aminophenylacetic acid
HMS2090C10
HMS501E04
HSDB 7234
I14-7739
IDI1_000272
IDI1_000402
ISV-205
KBio1_000272
KBio1_000402
KBio2_001410
KBio2_002306
KBio2_003978
KBio2_004874
KBio2_006546
KBio2_007442
KBio3_001389
KBio3_002786
KBioGR_001051
KBioGR_002306
KBioSS_001410
KBioSS_002308
Kriplex
Lopac0_000441
LS-11575
MolPort-000-003-072
N-(2,6-Dichlorop
NCGC00021125-01
Neriodin
NINDS_000272
NINDS_000402
Novapirina
Novo-Difenac
Novo-Difenac SR
Nu-Diclo
Oprea1_011155
Orthofen
Orthophen
Ortofen
Pennsaid
Prestwick0_000594
Prestwick1_000594
Prestwick2_000594
Prestwick3_000594
Primofenac
Prophenatin
ProSorb-D
Rhumalgan
SBB068617
Sodium diclofenac
Solaraze
Solaraze (TN)
Solaraze T
SPBio_001081
SPBio_002687
Spectrum_000930
Spectrum2_000991
Spectrum3_000385
Spectrum4_000506
Spectrum5_000867
SR 38
SR-38
STK984493
Transfenac
Tsudohmin
UNII-144O8QL0L1
UNM000001216103
Valetan
Voldal
Voltaflan
Voltaren
Voltaren Ophtha
Voltaren ophthalmic
Voltaren Ophthalmic
Voltaren Rapide
Voltaren SR
Voltaren-XR
Voltarol
Xenid
Zorvolex
|
|
2 |
|
Colchicine |
Approved |
Phase 4 |
|
64-86-8 |
6167 2833 |
Synonyms:
(S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide
30512-31-3
5843-86-7
64-86-8
7.alpha.H-Colchicine
7alphaH-Colchicine
7-alpha-H-Colchicine
AC1L1LXO
ACon1_000353
AI3-31149
AKOS001582887
BB_NC-0737
Benzo(a)heptalen-9(5H)-one
binds to tubulin
BPBio1_000535
BRD-K00259736-001-06-5
BSPBio_000485
BSPBio_002083
C 9754
C07592
C22H25NO6
C3915_SIGMA
C9754_SIGMA
CCRIS 691
CHEBI:27882
CHEMBL107
CID6167
Colchicin
Colchicin [German]
Colchicina
Colchicina [Italian]
colchicine
Colchicine
Colchicine (JP15/USP)
Colchicine (TN)
Colchicine [JAN]
Colchicine, (+-)-Isomer
Colchicine, (R)-Isomer
Colchicine, Colchicum autumnale
Colchicinum
Colchineos
Colchisol
Colchysat
Colcin
Colcrys
Colsaloid
Colstat
Condylon
CPD-9785
D003078
D00570
DB01394
DB08117
DivK1c_000753
EINECS 200-598-5
EU-0100310
Goutnil
HMS1569I07
HMS1920A08
HMS2091G16
HMS502F15
HSDB 3044
IDI1_000753
inhibits microtubular assembly
KBio1_000753
|
KBio2_001322
KBio2_003890
KBio2_006458
KBio3_001303
KBioGR_000856
KBioSS_001322
Kolkicin
LOC
Lopac0_000310
LS-279
MEGxp0_001879
MLS001055448
MLS001055448-02
MLS001304089
MLS002153786
MolPort-001-742-594
MPC-004
N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)- acetamide
N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide
N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide
N-Acetyl trimethylcolchicinic acid methylether
NCGC00025125-01
NCGC00025125-02
NCGC00025125-03
NCGC00025125-04
NCGC00025125-05
NCGC00025125-06
NCGC00025125-07
NCGC00025125-11
NCGC00169157-01
NCGC00169157-02
NCGC00169157-03
NChemBio.2007.10-comp20
nchembio853-comp2
NCI60_041659
NINDS_000753
NSC 757
NSC757
Prestwick_695
Prestwick0_000363
Prestwick1_000363
Prestwick2_000363
Prestwick3_000363
S2284_Selleck
SDCCGMLS-0066633.P001
SMR000058323
SPBio_000289
SPBio_002406
Spectrum_000842
SPECTRUM1500205
Spectrum2_000075
Spectrum3_000362
Spectrum4_000298
Spectrum5_000787
spindle poison
Tocris-1364
UNII-SML2Y3J35T
UPCMLD-DP065
UPCMLD-DP065:001
WLN: L B677 MV&T&J CO1 DO1 EO1 JMV1 NO1
ZINC00621853
|
|
3 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
4 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
5 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
6 |
|
Analgesics |
|
Phase 4 |
|
|
|
7 |
|
Cyclooxygenase Inhibitors |
|
Phase 4 |
|
|
|
8 |
|
Antimitotic Agents |
|
Phase 4 |
|
|
|
9 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
10 |
|
Tubulin Modulators |
|
Phase 4 |
|
|
|
11 |
|
Bleomycin |
Approved, Investigational |
Phase 3 |
|
11056-06-7 |
5360373 |
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
Almirall brand OF bleomycin sulfate
Bellon brand OF bleomycin sulfate
Bellon, bléomycine
Blanoxan
Blenoxane
Bleo
Bleo cell
Bleo-cell
BLEOcell
Bleocin
Bleogin
Bleolem
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
bleomycin
Bleomycin
Bleomycin a(2)
Bleomycin A(2)
bleomycin a2
Bleomycin a2
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin b(2)
Bleomycin B(2)
Bleomycin b2
Bleomycin B2
Bleomycin sulfate
|
Bleomycin sulphate
Bleomycine
Bleomycine [INN-French]
Bléomycine bellon
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
Bleomycinum mack
BLM
Bristol myers squibb brand OF bleomycin sulfate
Bristol-myers squibb brand OF bleomycin sulfate
Bull brand OF bleomycin sulfate
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
Cell pharm brand OF bleomycin sulfate
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
Lemery brand OF bleomycin sulfate
LMPK14000006
LS-44860
LS-524
Lundbeck brand OF bleomycin sulfate
Mack brand OF bleomycin sulfate
Mack, bleomycinum
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
Sulfate, bleomycin
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
|
|
12 |
|
Fibrinolytic Agents |
|
Phase 3 |
|
|
|
13 |
|
Plasminogen |
|
Phase 3 |
|
|
|
14 |
|
Tissue Plasminogen Activator |
|
Phase 3 |
|
|
|
15 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
16 |
|
Sclerosing Solutions |
|
Phase 3 |
|
|
|
17 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
18 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
19 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bris taxol
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
|
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL
TAXOL (TN)
Taxol a
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol, bris
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
20 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 498142 38904 |
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
|
DivK1c_000892
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
21 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
22 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
23 |
|
Erlotinib Hydrochloride |
|
Phase 2 |
|
183319-69-9 |
176871 |
Synonyms:
|
24 |
|
Albumin-Bound Paclitaxel |
|
Phase 2 |
|
|
|
25 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
26 |
|
Trastuzumab |
Approved, Investigational |
Phase 1 |
|
180288-69-1 |
9903 |
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
Herceptin (TN)
Ig gamma-1 chain C region
RHUMAB HER2
trastuzumab
|
Trastuzumab
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
Trastuzumab (INN)
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
27 |
|
Adjuvants, Immunologic |
|
Phase 1 |
|
|
|
28 |
|
Immunologic Factors |
|
Phase 1 |
|
|
|
29 |
|
Interleukin-12 |
|
Phase 1 |
|
|
|
30 |
|
Carbon monoxide |
Approved, Investigational |
|
|
630-08-0 |
281 |
Synonyms:
[CO]
C#O
Carbon monoxide
carbon(II) oxide
|
Carboneum oxygenisatum
CO
Monoxide, carbon
|
|
31 |
|
Nitric Oxide |
Approved |
|
|
10102-43-9 |
145068 |
Synonyms:
(.)NO
(NO)(.)
[NO]
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous nitrate vasodilator
Endogenous Nitrate Vasodilator
Endothelium-derived nitric oxide
Endothelium-Derived Nitric Oxide
endothelium-derived relaxing factor
Endothelium-derived relaxing factor
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, Mononitrogen
Monoxide, nitrogen
Monoxide, Nitrogen
monoxido de nitrogeno
Monoxido de nitrogeno
Monóxido de nitrógeno
monoxyde d'azote
Monoxyde d'azote
Nitrate vasodilator, endogenous
Nitrate Vasodilator, Endogenous
nitric oxide
|
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, endothelium derived
Nitric Oxide, Endothelium Derived
Nitric oxide, endothelium-derived
Nitric Oxide, Endothelium-Derived
NITRIC-OXIDE
nitrogen monooxide
Nitrogen monooxide
nitrogen monoxide
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
nitrosyl
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
NO(.)
OHM 11771
Oxide, nitric
Oxide, Nitric
oxido de nitrogeno(II)
Oxido de nitrogeno(II)
óxido de nitrógeno(II)
oxido nitrico
Oxido nitrico
óxido nítrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, endogenous nitrate
Vasodilator, Endogenous Nitrate
|
|
32 |
|
Aspirin |
Approved, Vet_approved |
|
|
50-78-2 |
2244 |
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoate
2-(ACETYLOXY)benzoIC ACID
2349-94-2
26914-13-6
2-Acetoxybenzenecarboxylate
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. empirin
A.S.A. Empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
acide 2-(acétyloxy)benzoïque
Acide acetylsalicylique
Acide acétylsalicylique
Acido acetilsalicilico
ácido acetilsalicílico
Acido O-acetil-benzoico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
AI3-02956
AIN
AKOS000118884
Aloxiprimum
ASA
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspirdrops
aspirin
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina
Aspirina 03
Aspirine
Aspir-Mox
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bialpirina
Bialpirinia
BIDD:GT0118
Bi-prin
BRN 0779271
Bufferin
C01405
Caprin
Cardioaspirin
Cardioaspirina
CCRIS 3243
Cemirit
CHEBI:15365
CHEMBL25
CID2244
Claradin
Clariprin
cMAP_000006
Colfarit
component of Midol
component of Synirin
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
Durlaza
Easprin
Easprin (TN)
ECM
Ecolen
Ecotrin
EINECS 200-064-1
Empirin
|
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EU-0100038
Extren
Globentyl
Globoid
Helicon
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
I14-7505
IDI1_000555
Idragin
Istopirin
Kapsazal
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
Levius
Lopac0_000038
Lopac-A-5376
LS-143
Magnecyl
Measurin
Medisyl
Micristin
MLS001055329
MLS001066332
MLS001336045
MLS001336046
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
nchem.859-comp6
NCI60_002222
Neuronika
NINDS_000555
Novid
NSC 27223
NSC27223
NSC406186
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-accetylsalicylic acid
O-Acetoxybenzoate
o-acetoxybenzoic acid
o-Acetoxybenzoic acid
O-Acetoxybenzoic acid
O-Acetylsalicylate
O-acetylsalicylic acid
O-Acetylsalicylic acid
o-carboxyphenyl acetate
o-Carboxyphenyl acetate
O-Carboxyphenyl acetate
O-Carboxyphenyl acetic acid
Persistin
Pharmacin
Pirseal
PL-2200
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
Salacetin
Salcetogen
Saletin
Salicylate acetate
Salicylic acid acetate
Salicylic acid acetic acid
Salicylic acid, acetate
Salospir
SMR000059138
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
SP 189
SPBio_001838
Spectrum_001245
SPECTRUM1500130
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
ST075414
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII=R16CO5Y76E
UNII-R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
Xaxa
XAXA
Yasta
Zorprin
ZORprin
|
|
33 |
|
Kava |
Approved, Investigational, Nutraceutical |
|
|
9000-38-8 |
|
34 |
|
Brimonidine Tartrate |
|
|
|
70359-46-5 |
|
35 |
|
Immunoglobulins |
|
|
|
|
|
36 |
|
Antibodies |
|
|
|
|
|
37 |
|
Antibodies, Monoclonal |
|
|
|
|
|
38 |
|
Respiratory System Agents |
|
|
|
|
|
39 |
|
Anesthetics |
|
|
|
|
|
40 |
|
Tin Fluorides |
|
|
|
|
|
41 |
|
Anticoagulants |
|
|
|
|
|
Interventional clinical trials:
(show all 29)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters |
Unknown status |
NCT02808897 |
Phase 4 |
|
2 |
the Post Operative Pericardial Effusion (POPE) Treatment Study |
Completed |
NCT00247052 |
Phase 4 |
diclofenac;diclofenac;matching placebo |
3 |
Cochicine Treatment for Post- Operative Pericardial Effusion: The POPE 2 Study A Multicenter, Double-blind, Randomized Trial |
Completed |
NCT01266694 |
Phase 4 |
Colchicines;Placebo |
4 |
Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion Following Catheter Ablation of Atrial Fibrillation |
Recruiting |
NCT02260206 |
Phase 4 |
Colchicine |
5 |
COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 Trial). |
Unknown status |
NCT01552187 |
Phase 3 |
Colchicine;Placebo |
6 |
A Trial of Complete Percutaneous Pericardial Drainage Facilitated by Intrapericardial Alteplase Compared to Conventional Pericardiocentesis When Indicated in Adults With Large Pericardial Effusion Due to Tuberculous and Non-tuberculous Pericarditis |
Unknown status |
NCT02673879 |
Phase 3 |
|
7 |
A Randomized Controlled Trial to Evaluate the Efficacy of Intra-pericardial Instillation of a Sclerosing Agent After Pericardial Drainage in Patients With Malignant Pericardial Effusion Associated With Lung Cancer (JCOG9811) |
Completed |
NCT00132613 |
Phase 3 |
Pericardial instillation of bleomycin after drainage |
8 |
Colchicine in Postoperative Fontan Patients (CPFP) |
Recruiting |
NCT03575572 |
Phase 2, Phase 3 |
Colchicine |
9 |
Intrapleural Bevacizumab Injection for Treating Malignant Pleural or Pericardial Effusion in Non-small Cell Lung Cancer |
Completed |
NCT02054052 |
Phase 2 |
Bevacizumab |
10 |
A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and / or Refractory Stage IIIb (With Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients |
Completed |
NCT00431015 |
Phase 1, Phase 2 |
IPI-504 |
11 |
A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers |
Completed |
NCT00126581 |
Phase 2 |
Carboplatin;Erlotinib;Erlotinib Hydrochloride;Paclitaxel |
12 |
A Phase I Trial of Herceptin and Interleukin-12 |
Completed |
NCT00004074 |
Phase 1 |
|
13 |
Drainage or Pericardiocentesis Alone for Recurrent Non-malignant Pericardial Effusions Requiring Intervention. |
Unknown status |
NCT01665495 |
|
|
14 |
Evaluation of Different Strategies of Pericardial Drainage After Aortic Valvular Surgery: A Prospective Randomized Trial |
Completed |
NCT00684125 |
|
|
15 |
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath |
Completed |
NCT02638649 |
|
|
16 |
The Clinical Impact of an Aggressive Approach Towards Pleural and Pericardial Effusions Following Open Heart Surgery: a Step Towards Standard Guidelines |
Completed |
NCT02045641 |
|
|
17 |
Feasibility and Accuracy of Focused Cardiac Ultrasound Using an FDA Approved Hand-held Ultrasound Device in Outpatient Setting in Our Institution. |
Completed |
NCT03887286 |
|
|
18 |
A Randomized Prospective Study of the Definitive Management of the Stable Haemopericardium Following Penetrating Cardiac Injury Utilising Subxyphoid Window and Drainage. |
Completed |
NCT00823160 |
|
|
19 |
Primary Percutaneous Pericardiotomy for Malignant Pericardial Effusion (PMAP) - A Randomized Study |
Recruiting |
NCT04472468 |
|
|
20 |
Screening of Pulmonary Veino Occlusive Disease in Heterozygous EIF2AK4 Mutation Carriers |
Recruiting |
NCT03902353 |
|
|
21 |
Monitoring Patients With Acute Dyspnea With Serial Focused Ultrasound of the Heart and the Lungs |
Recruiting |
NCT04091334 |
|
|
22 |
Establishment of Patient Derived Cancer Cell Models to Interrogate Novel Molecular Targets in Metastatic Cancer |
Recruiting |
NCT02646228 |
|
|
23 |
Diagnostic Value of Cell Block Immunohistochemistry in Effusion Cytology |
Recruiting |
NCT04279327 |
|
|
24 |
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease |
Recruiting |
NCT04464655 |
|
|
25 |
Point-of-care Ultrasound in Finland |
Recruiting |
NCT03327688 |
|
|
26 |
Cardiovascular Manifestation of Inflamatory Bowel Disease Patient ( Tissue Doppler Echocardiography and Cardiac MRI ) |
Not yet recruiting |
NCT04656015 |
|
|
27 |
Study of the Effects of Anticoagulant Interruption Covered by Percutaneous Left Atrial Occlusion in Patients With Chronic Atrial Fibrillation and Radiation Cystitis at Risk of Bleeding |
Not yet recruiting |
NCT04701749 |
|
|
28 |
CancerCodeTM Informed, Molecularly Targeted Therapies in Non-small Cell Lung Cancer |
Terminated |
NCT02132884 |
|
targeted therapy |
29 |
A Randomized, Prospective Study on Point-of-Care Focused Cardiac Ultrasound in Patients Presenting to the Emergency Department With Syncope |
Terminated |
NCT01671371 |
|
|
|